FDA grants fast track status to Artiva's AlloNK for lupus nephritis

The US FDA has granted fast track designation to Artiva Biotherapeutics’ AlloNK plus rituximab or obinutuzumab, for the treatment of lupus nephritis (LN).

Related Keywords

Fred Aslan , ,